GN
GNPX
HealthcareGenprex, Inc.
Biotechnology
Total Trades
4
Unique Traders
1
Purchases / Sales
4/0
News Articles
5
Trading History
| Date | Politician | Asset | Action | Amount | Trade Price | 30D Price | 1M Return | Alpha | 1M Prediction |
|---|---|---|---|---|---|---|---|---|---|
Feb 5, 2026 |  Tim MooreR | Stock | Buy | $1,001 - $15,000 | $1.96 | $1.95 | -0.5% | +0.3% | |
Dec 18, 2025 | Tim MooreR | Stock | Buy | $1,001 - $15,000 | $2.17 | $3.00 | +38.2% | +35.7% | |
Nov 7, 2025 | Tim MooreR | Stock | Buy | $1,001 - $15,000 | $4.21 | $3.36 | -20.2% | -22.4% | |
Oct 29, 2025 | Tim MooreR | Stock | Buy | $15,001 - $50,000 | $6.64 | $2.96 | -55.4% | -54.8% |
Recent News
Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers
Yahoo-Invalid Date
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga-Invalid Date
Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer
Yahoo-Invalid Date
Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules
Yahoo-Invalid Date
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Yahoo-Invalid Date